vWD
![]() | Prophylaxis in Patients with Von Willebrand Disease: Expert Perspectives and Shared Experiences CME, CNE Robert F. Sidonio, Jr., MD, Miguel A. Escobar, MD, Angela C. Weyand, MD | |
Release Date: September 27, 2022 Expiration Date: September 27, 2023 | ||
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder in the United States. Despite this, however, many healthcare professionals lack the knowledge required to diagnose or treat VWD. This activity addresses the importance of long-term prophylaxis in VWD on guideline recommendations for long-term prophylaxis, and on emerging data regarding novel agents for prophylaxis in this disease. This program will conclude with case discussions designed to improve the awareness concerning symptoms of VWD and diagnostic assessments in order to better manage and treat the patients in your practice. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. | ||
Begin, Earn CreditView Only, No Credit | ||